Decision points to enter and exit the human cell cycle

进入和退出人体细胞周期的决策点

基本信息

  • 批准号:
    9270039
  • 负责人:
  • 金额:
    $ 28.33万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-05-09 至 2018-03-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Diseases associated with cancer, immune responses, wound healing, and neurodegeneration are often caused by insufficient or excessive proliferation of particular human cell types. Under normal conditions, such cells have to robustly control if and when they proliferate to maintain and repair functioning tissues. While little is known about how cells exit the cell cycle, the decision to enter the cell cycle is often referred t as a "restriction point", a point where growth factors can be removed and cells still enter and complete the cell cycle. However, our recent single cell data analysis suggests that this fundamentally important decision is made by a different mechanism involving a cell cycle priming and a final cell cycle commitment step. Our proposed work will make use of automated single live cell and fixed cell analysis using biosensor and activity selective antibodies to measure key cell cycle regulatory events and to dissect the control circuits of cell cycle entry and exit. Our final goal is to develop and validate a quantitative model for cell cycle entry and exit. The outcome of the proposed work will be the identification, characterization and modeling of critical proliferation control points that can be exploited therapeutically to treat diseases suh as cancer, immune responses, wound healing, as well as neurodegenerative diseases. For many growth associated diseases, treatment will likely involve strategies to regulate the rate of proliferation of specific cell types. In addition, our work will provide the cell cycle and cancer research communities with experimental and modeling tools to investigate cell specific cell cycle control in different cell types.
 描述(由申请人提供):与癌症、免疫反应、伤口愈合和神经变性相关的疾病通常由特定人类细胞类型的增殖不足或过度引起。在正常情况下,这些细胞必须强有力地控制它们是否以及何时增殖以维持和修复功能组织。虽然对细胞如何退出细胞周期知之甚少,但进入细胞周期的决定通常被称为“限制点”,即生长因子可以被去除而细胞仍然进入并完成细胞周期的点。然而,我们最近的单细胞数据分析表明,这一根本性的重要决定是由一个不同的机制,涉及细胞周期启动和最终的细胞周期承诺步骤。我们提出的工作将利用自动化的单个活细胞和固定细胞分析,使用生物传感器和活性选择性抗体来测量关键的细胞周期调控事件,并剖析细胞周期进入和退出的控制电路。我们的最终目标是开发和验证细胞周期进入和退出的定量模型。拟议的工作的结果将是识别,表征和建模的关键增殖控制点,可以利用治疗疾病,如癌症,免疫反应,伤口愈合,以及神经退行性疾病。对于许多生长相关疾病,治疗可能涉及调节特定细胞类型增殖速率的策略。此外,我们的工作将为细胞周期和癌症研究社区提供实验和建模工具,以研究不同细胞类型中的细胞特异性细胞周期控制。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Irreversible APC(Cdh1) Inactivation Underlies the Point of No Return for Cell-Cycle Entry.
  • DOI:
    10.1016/j.cell.2016.05.077
  • 发表时间:
    2016-06-30
  • 期刊:
  • 影响因子:
    64.5
  • 作者:
    Cappell SD;Chung M;Jaimovich A;Spencer SL;Meyer T
  • 通讯作者:
    Meyer T
Measuring Signaling and RNA-Seq in the Same Cell Links Gene Expression to Dynamic Patterns of NF-κB Activation.
  • DOI:
    10.1016/j.cels.2017.03.010
  • 发表时间:
    2017-04-26
  • 期刊:
  • 影响因子:
    9.3
  • 作者:
    Lane K;Van Valen D;DeFelice MM;Macklin DN;Kudo T;Jaimovich A;Carr A;Meyer T;Pe'er D;Boutet SC;Covert MW
  • 通讯作者:
    Covert MW
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TOBIAS MEYER其他文献

TOBIAS MEYER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TOBIAS MEYER', 18)}}的其他基金

Cell Signaling and Cell Decisions
细胞信号传导和细胞决策
  • 批准号:
    10393574
  • 财政年份:
    2018
  • 资助金额:
    $ 28.33万
  • 项目类别:
Cell Signaling and Cell Decisions
细胞信号传导和细胞决策
  • 批准号:
    10292339
  • 财政年份:
    2018
  • 资助金额:
    $ 28.33万
  • 项目类别:
Cell Signaling and Cell Decisions
细胞信号传导和细胞决策
  • 批准号:
    9912173
  • 财政年份:
    2018
  • 资助金额:
    $ 28.33万
  • 项目类别:
Cell Signaling and Cell Decisions
细胞信号传导和细胞决策
  • 批准号:
    10560042
  • 财政年份:
    2018
  • 资助金额:
    $ 28.33万
  • 项目类别:
CV7000
CV7000
  • 批准号:
    8640626
  • 财政年份:
    2014
  • 资助金额:
    $ 28.33万
  • 项目类别:
2011 Gradient Sensing and Directed Cell Migration Gordon Research Conference
2011 梯度传感和定向细胞迁移戈登研究会议
  • 批准号:
    8128064
  • 财政年份:
    2011
  • 资助金额:
    $ 28.33万
  • 项目类别:
Control of Hedgehog Signal Transduction by Neuropilin
Neuropilin 对 Hedgehog 信号转导的控制
  • 批准号:
    8620669
  • 财政年份:
    2011
  • 资助金额:
    $ 28.33万
  • 项目类别:
Bar Domains and Neuronal Membrane Structure
Bar 结构域和神经元膜结构
  • 批准号:
    8325094
  • 财政年份:
    2011
  • 资助金额:
    $ 28.33万
  • 项目类别:
Bar Domains and Neuronal Membrane Structure
Bar 结构域和神经元膜结构
  • 批准号:
    8470247
  • 财政年份:
    2011
  • 资助金额:
    $ 28.33万
  • 项目类别:
Bar Domains and Neuronal Membrane Structure
Bar 结构域和神经元膜结构
  • 批准号:
    8679000
  • 财政年份:
    2011
  • 资助金额:
    $ 28.33万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 28.33万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 28.33万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 28.33万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.33万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 28.33万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 28.33万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 28.33万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 28.33万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 28.33万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 28.33万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了